CD BioGlyco has a professional carbohydrate-based glycomedicine development platform with multiple world-leading technologies to help customers comprehensively promote the development of carbohydrate-based antiviral glycomedicines.
Viral pathogens have been one of the great threats to public health throughout human history, accounting for more than 60 percent of past pandemics, including the outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002-2003. Asian hghly pathogenic avian influenza (HPAI) A (H5N1) in 2009 and 2010, Middle East respiratory syndrome coronavirus (MERSCoV) in 2012, Ebola virus in West Africa in 2014-2016, as well as the ongoing coronavirus disease 2019 (COVID-19) 56-58. Besides, there is still no complete cure for acquired immune deficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) and hepatitis B disease caused by hepatitis B virus (HBV). Current treatments of HIV and HBV can only maintain low levels of the virus through lifelong antiviral therapy.
The carbohydrate-based molecules show unique advantages in antiviral drug discovery. Nucleoside and nucleotide could selectively interrupt the replication of the viral RNA or DNA61. This mechanism lays the foundation for the development of carbohydrate-based antiviral glycomedicines.
Fig.1 Carbohydrate-based drugs for COVID-19. (Cao, et al., 2022)
As a leading resource provider in the glycobiology field, CD BioGlyco has various systematic services for the development of carbohydrate-based antiviral glycomedicines. Our services include but are not limited to:
With extensive experience, rich industry knowledge and advanced glycomedicine development technologies, CD BioGlyco is exactly competent in a full spectrum of carbohydrate-based antiviral glycomedicine development services. We are confident in accomplishing even the most challenging engineering project with a short turnaround time. To learn more, please don't hesitate to contact us to learn how we can help you with your project.
Reference:
